STATEMENT OF NEED

Progressive familial intrahepatic cholestasis (PFIC) is a group of rare liver disorders that can now be identified through genetic testing, enabling earlier diagnosis and intervention to prevent progressive liver damage. PFIC is caused by mutations in the genes coding for proteins involved in bile formation and transport (McKiernan et al, 2023). While genetic cholestatic liver diseases have historically been considered severe, recessive pediatric disorders, advances in genome sequencing have contributed to a growing awareness of these diseases in adults. Diagnosis of adult-onset PFIC is complicated by its rarity, confusion with other hepatic diseases, and a broad spectrum of clinical presentations, including elevated liver enzymes, pruritus, drug-induced liver injury, or gallstones, which significantly impact quality of life. When not detected and treated early, PFIC can progress to end-stage liver disease. Genetic testing is an essential step in identifying PFIC and facilitating personalized management strategies that provide symptom relief and prevent complications (Thompson et al, 2025; Nasir et al, 2026). This Virtual Escape Room follows 2 patients with PFIC, Steve and Jane, through their diagnosis and treatment journeys. Join Aparna Goel, MD, Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford School of Medicine, and Laura Bull, PhD, RDN, Professor in the Department of Medicine at the University of California, San Francisco, to decipher the role of genetics in the diagnosis and treatment of PFIC.

TARGET AUDIENCE

Adult hepatologists, adult hepatology advanced practice providers, and other clinicians involved in the care of adults with PFIC.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Appraise signs, symptoms, and laboratory results that raise clinical suspicion of PFIC in adults
• Utilize the results of genetic testing to inform PFIC diagnosis
• Assess evidence concerning how therapeutic decision making should be influenced by genotype in adult patients with PFIC
• Evaluate strategies to promote effective communication of genetic testing results with patients and families 

 
REGISTRATION

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 4/29/27. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Aparna Goel, MD​, discloses that she has served on an advisory board or panel for Gilead, Kezar, and Mirum; that she has served as a consultant for Amgen, Dren Bio, and RegCell; and that she has received grants/research support from Gilead.

Laura Bull, PhD, RDN​, discloses that she has served on an advisory board or panel for Ipsen and that she has served as a consultant for Ipsen. 

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CPE ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by a medical education grant from Ipsen Biopharmaceuticals, Inc.

Aggregate participant data will be shared with commercial supporters of this activity.

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.